PKM and non-small cell lung carcinoma: Most importantly, a strong association between the CSC marker CD133 and phosphorylated PKM2, but not its unmodified form, underscores that PKM2 phosphorylation at Y105 is a critical determinant of cancer cell stemness and drug resistance in NSCLC, and we confirmed this by constructing point mutation cells.